Noncultured epidermal cell suspension for the treatment of recalcitrant segmental vitiligo in a solid-organ transplant recipient

Dellatorre, Gerson; Castro, Caio César Silva de

doi:10.1016/j.abd.2019.02.014

Cited by 1 publication

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Guidelines from the Argentinian Society of Dermatology are also available (Supplementary Table ) 78 . Brazilian, Argentinian and international guidelines define standard treatment as TCS and calcineurin inhibitors for unstable and localized cases and corticosteroid oral mini‐pulse therapy for unstable generalized cases 1,79 . In the few regional studies that included information about treatment, TCS were commonly used in Brazilian and Tanzanian patients 22,30 .…”

Section: Disease Management and Treatmentmentioning

confidence: 99%

“…Brazilian guidelines recommend that surgical modalities be reserved primarily for stable segmental disease and generalized vitiligo, with phototherapy before and after surgical treatment 74 . Pilot studies involving suction blister epidermal graft and non‐cultured epidermal cell suspension for surgical vitiligo management were recently conducted in Brazil 79,83 . In the Middle East, transplants of epidermal cell suspension (melanocytes and keratinocytes) are increasingly being used and have been well documented by different groups 84–87 …”

Section: Disease Management and Treatmentmentioning

confidence: 99%

“…74 Pilot studies involving suction blister epidermal graft and non-cultured epidermal cell suspension for surgical vitiligo management were recently conducted in Brazil. 79,83 In the Middle East, transplants of epidermal cell suspension (melanocytes and keratinocytes) are increasingly being used and have been well documented by different groups. [84][85][86][87] Tailored personalized treatment is required for optimal treatment of vitiligo, and some patients prefer cosmetic camouflage or depigmentation approaches.…”

Section: Disease Management and Treatment Guidelinesmentioning

confidence: 99%

“…78 Brazilian, Argentinian and international guidelines define standard treatment as TCS and calcineurin inhibitors for unstable and localized cases and corticosteroid oral mini-pulse therapy for unstable generalized cases. 1,79 In the few regional studies that included information about treatment, TCS were commonly used in Brazilian and Tanzanian patients. 22,30 Brazilian guidelines, published prior to the FDA approval of ruxolitinib in 2022, also highlighted that topical and systemic anti-Janus kinase agents and anti-interleukin 15 receptor immunobiologicals are in development.…”

Section: Disease Management and Treatment Guidelinesmentioning

confidence: 99%

See 3 more Smart Citations

Prevalence and burden of vitiligo in Africa, the Middle East and Latin America

Al Hammadi,

Silva de Castro,

Parmar

et al. 2023

Skin Health and Disease

View full text Add to dashboard Cite

Vitiligo is a common chronic autoimmune disorder characterized by skin and hair depigmentation that affects 0.5%–2.0% of the global population. Vitiligo is associated with diminished quality of life (QoL) and psychosocial burden. The burden of vitiligo may vary based on skin tone and cultural differences as well as geographical variations in disease awareness, societal stigma, healthcare systems and treatment options. Data on the burden and management of vitiligo in Africa, the Middle East and Latin America are scarce. Literature searches using terms covering vitiligo in Africa, the Middle East and Latin America were conducted using PubMed to identify relevant publications that focused on disease prevalence and burden, QoL and psychosocial impact and disease management between 2011 and 2021. Most of the reviewed studies were conducted in the Middle East, and most Latin American studies were from Brazil. Most studies involved small patient numbers and may not be generalizable. Reported prevalence of vitiligo ranged from 0.18% to 5.3% in Africa and the Middle East, and from 0.04% to 0.57% in Latin America. In several studies, prevalence was higher among female participants. Generally, non‐segmental vitiligo was the dominant clinical variant identified and the age at onset varied widely across studies. Common comorbidities include autoimmune diseases such as Hashimoto's thyroiditis, alopecia areata and diabetes. Few treatment guidelines exist in these regions, with the exceptions of guidelines published by the Brazilian and Argentinian Societies of Dermatology. There is a clear unmet need for large epidemiological studies with uniform methodology to accurately ascertain the true prevalence of vitiligo in Africa, the Middle East and Latin America. Additional data on vitiligo burden and management in Africa and Latin America are also needed, along with local disease management guidelines that consider genetic variation, psychosocial burden and socioeconomic diversity in all 3 regions.

show abstract

Section: Disease Management and Treatmentmentioning

confidence: 99%